Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response

• Published in: Cancers 2020-08, Vol.12 (8), p.2072
• Main Authors: van der Kooij, Monique K., Wetzels, Marjolein J.A.L., Aarts, Maureen J.B., van den Berkmortel, Franchette W.P.J., Blank, Christian U., Boers-Sonderen, Marye J., Dierselhuis, Miranda P., de Groot, Jan Willem B., Hospers, Geke A.P., Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P.M., ten Tije, Albert J., van der Veldt, Astrid A.M., Vreugdenhil, Gerard, Wouters, Michel W.J.M., Haanen, John B.A.G., van den Eertwegh, Alfonsus J.M., Bastiaannet, Esther, Kapiteijn, Ellen
• Format: Article
• Language: English
• Subjects: Adolescents; Age; Clinical trials; Cohort analysis; Colitis; Comparative analysis; CTLA-4 protein; Hepatitis; Inflammatory bowel disease; Medical prognosis; Melanoma; Mutation; Older people; Oncology; Patients; PD-1 protein; Physiological aspects; Survival; Teenagers; Toxicity; Young adults
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers12082072

Cutaneous melanoma is a common type of cancer in Adolescents and Young Adults (AYAs, 15–39 years of age). However, AYAs are underrepresented in clinical trials investigating new therapies and the outcomes from these therapies for AYAs are therefore unclear. Using prospectively collected nation-wide data from the Dutch Melanoma Treatment Registry (DMTR), we compared baseline characteristics, mutational profiles, treatment strategies, grade 3–4 adverse events (AEs), responses and outcomes in AYAs (n = 210) and older adults (n = 3775) who were diagnosed with advanced melanoma between July 2013 and July 2018. Compared to older adults, AYAs were more frequently female (51% versus 40%, p = 0.001), and had a better Eastern Cooperative Oncology Group performance status (ECOG 0 in 54% versus 45%, p = 0.004). BRAF and NRAS mutations were age dependent, with more BRAF V600 mutations in AYAs (68% versus 46%) and more NRAS mutations in older adults (13% versus 21%), p < 0.001. This finding translated in distinct first-line treatment patterns, where AYAs received more initial targeted therapy. Overall, grade 3–4 AE percentages following first-line systemic treatment were similar for AYAs and older adults; anti-PD-1 (7% versus 14%, p = 0.25), anti-CTLA-4 (16% versus 33%, p = 0.12), anti-PD-1 + anti-CTLA-4 (67% versus 56%, p = 0.34) and BRAF/MEK-inhibition (14% versus 23%, p = 0.06). Following anti-CTLA-4 treatment, no AYAs experienced a grade 3–4 colitis, while 17% of the older adults did (p = 0.046). There was no difference in response to treatment between AYAs and older adults. The longer overall survival observed in AYAs (hazard ratio (HR) 0.7; 95% CI 0.6–0.8) was explained by the increased cumulative incidence of non-melanoma related deaths in older adults (sub-distribution HR 2.8; 95% CI 1.5–4.9), calculated by competing risk analysis. The results of our national cohort study show that baseline characteristics and mutational profiles differ between AYAs and older adults with advanced melanoma, leading to different treatment choices made in daily practice. Once treatment is initiated, AYAs and older adults show similar tumor responses and melanoma-specific survival.